The germline sequence variant rs2736100_C in TERT associates with myeloproliferative neoplasms
暂无分享,去创建一个
A Sigurdsson | G Masson | D. Gudbjartsson | A. Sigurdsson | Á. Jónasdóttir | U. Thorsteinsdóttir | A. Kong | K. Stefánsson | H. Helgason | P. Sulem | G. Eyjolfsson | I. Olafsson | P. T. Onundarson | O. Sigurdardottir | G. Másson | T. Rafnar | H. Steingrímsdóttir | A. Oddsson | A Oddsson | S Y Kristinsson | H Helgason | D F Gudbjartsson | A Jonasdottir | H Steingrimsdottir | B Vidarsson | S Reykdal | G I Eyjolfsson | I Olafsson | P T Onundarson | G Runarsson | O Sigurdardottir | A Kong | T Rafnar | P Sulem | U Thorsteinsdottir | K Stefansson | D. Gudbjartsson | S. Kristinsson | B. Vidarsson | S. Reykdal | H. Helgason | G. Runarsson
[1] C B Harley,et al. Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.
[2] A. Jones,et al. Inherited predisposition to myeloproliferative neoplasms , 2013, Therapeutic advances in hematology.
[3] A. Tefferi,et al. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival , 2010, Leukemia.
[4] T. Barbui,et al. Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy. , 2013, Experimental hematology.
[5] These authors contributed equally to this work. , 2007 .
[6] Yusuke Nakamura,et al. Genome-wide association study of hematological and biochemical traits in a Japanese population , 2010, Nature Genetics.
[7] Gary L. Gallia,et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal , 2013, Proceedings of the National Academy of Sciences.
[8] Wei Lu,et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer , 2013, Nature Genetics.
[9] Andrew Collins,et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms , 2009, Nature Genetics.
[10] K. Pooley,et al. Telomerase reverse transcriptase locus polymorphisms and cancer risk: a field synopsis and meta-analysis. , 2012, Journal of the National Cancer Institute.
[11] Kenneth Offit,et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms , 2009, Nature Genetics.
[12] B. Fridley,et al. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. , 2008, Blood.
[13] P. O’Reilly,et al. Identification of seven loci affecting mean telomere length and their association with disease , 2013, Nature Genetics.
[14] Paolo Vineis,et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types , 2009, Nature Genetics.
[15] Cheng Huang,et al. Feedback regulation of telomerase reverse transcriptase: new insight into the evolving field of telomerase in cancer. , 2013, Cellular signalling.